Biodesix Inc (BDSX)vsMerck & Company Inc (MRK)
BDSX
Biodesix Inc
$28.43
-2.64%
HEALTHCARE · Cap: $284.51M
MRK
Merck & Company Inc
$149.57
+1.79%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 64568% more annual revenue ($66.57B vs $102.94M). MRK leads profitability with a 4.8% profit margin vs -27.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
BDSX
Avoid29
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-8.5%
Fair Value
$9.54
Current Price
$28.43
$18.89 premium
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$149.57
$66.53 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.2% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 32.7x book value
ROE of -349.9% — below average capital efficiency
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 34.2% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.85 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BDSX carries more volatility with a beta of 0.59 — expect wider price swings.
BDSX is growing revenue faster at 34.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?